Cullinan Oncology LLC

NASDAQ CGEM

Download Data

Cullinan Oncology LLC Market Capitalization on May 17, 2024: USD 1.34 B

Cullinan Oncology LLC Market Capitalization is USD 1.34 B on May 17, 2024, a 279.41% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.
  • Cullinan Oncology LLC 52-week high Market Capitalization is USD 1.54 B on May 15, 2024, which is 15.32% above the current Market Capitalization.
  • Cullinan Oncology LLC 52-week low Market Capitalization is USD 337.54 M on December 12, 2023, which is -74.72% below the current Market Capitalization.
  • Cullinan Oncology LLC average Market Capitalization for the last 52 weeks is USD 554.62 M.
NASDAQ: CGEM

Cullinan Oncology LLC

CEO Mr. Nadim Ahmed
IPO Date Jan. 8, 2021
Location United States
Headquarters One Main Street, Cambridge, MA, United States, 02142
Employees 85
Sector Healthcare
Industry Biotechnology
Description

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

USD 16.18

0.94%

IPSC

Century Therapeutics Inc

USD 3.01

-3.83%

EWTX

Edgewise Therapeutics Inc

USD 18.11

-0.39%

ACET

Adicet Bio Inc

USD 1.60

1.91%

VOR

Vor Biopharma Inc

USD 1.81

0.56%

GLUE

Monte Rosa Therapeutics Inc

USD 5.20

-0.38%

THRX

Theseus Pharmaceuticals Inc

USD 4.06

0.00%

StockViz Staff

May 20, 2024

Any question? Send us an email